- ICH GCP
- USA klinikai vizsgálatok nyilvántartása
- Klinikai vizsgálat NCT02170909
Safety, Pharmacokinetics and Pharmacodynamics of BIBR 1048 MS Capsule in Healthy Male Subjects of Japanese and Caucasian Origin
2018. augusztus 29. frissítette: Boehringer Ingelheim
Safety, Pharmacokinetics and Pharmacodynamics After Single (150 mg, 220 mg and 300 mg) and Multiple (150 mg and 220 mg q.d. and 150 mg b.i.d.) Rising Oral Doses of BIBR 1048 MS/Capsules in Healthy Male Subjects of Japanese and Caucasian Origin. (Open Label Study)
Study to investigate and compare safety, pharmacokinetics and pharmacodynamics of BIBR 1048 MS following oral administration of single (150 mg, 220 mg and 300 mg) and multiple (150 mg and 220 mg q.d. and 150 mg b.i.d.) rising doses in healthy male subjects of Japanese and Caucasian origin.
A tanulmány áttekintése
Állapot
Befejezve
Körülmények
Beavatkozás / kezelés
Tanulmány típusa
Beavatkozó
Beiratkozás (Tényleges)
42
Fázis
- 1. fázis
Részvételi kritériumok
A kutatók olyan embereket keresnek, akik megfelelnek egy bizonyos leírásnak, az úgynevezett jogosultsági kritériumoknak. Néhány példa ezekre a kritériumokra a személy általános egészségi állapota vagy a korábbi kezelések.
Jogosultsági kritériumok
Tanulmányozható életkorok
20 év (Felnőtt)
Egészséges önkénteseket fogad
Nem
Tanulmányozható nemek
Férfi
Leírás
Inclusion Criteria:
Healthy male subjects of Japanese or Caucasian origin according to the following criteria: Based upon a complete medical history, including the physical examination, vital signs (blood pressure, pulse rate, respiratory rate and tympanic body temperature), 12- lead ECG (electrocardiogram), clinical laboratory tests
- 1.1 No finding deviating from normal and of clinical relevance
- 1.2 No evidence of a clinically relevant concomitant disease
- Age ≥ 20 and Age ≤ 45 years
- Body mass index (BMI) ≥ 18 and ≤ 25 kg/m2
- Japanese subjects were from a well-defined Japanese population, both parents of Japanese origin and the subjects have Japanese passport and had lived ≤ 8 years outside Japan.
- Signed and dated written informed consent prior to admission to the study in accordance with GCP (Good Clinical Practice) and the local legislation.
Exclusion Criteria:
- Current gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
- An unwillingness of male subjects to abstain from sexual intercourse with pregnant or lactating women, or an unwillingness of male subjects to use an adequate form of contraception as well as having their female partner(s) use another form of contraception (if the woman possibly become pregnant) from the time of the single dose on Day 1 until Day 22-26 (end-of study examination)
- Current diseases of the central nervous system (such as epilepsy), or psychiatric disorders or neurological disorders
- History of clinically significant orthostatic hypotension, clinically significant current or past fainting spells or blackouts
- Chronic or relevant acute infections
History of
- allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator
- any bleeding disorder including prolonged or habitual bleeding
- other hematologic disease
- cerebral bleeding (e.g. after a car accident)
- concussions (head trauma resulting in injuring to brain) with or without loss of consciousness
- Intake of drugs with a long half-life (> 24 hours) within at least one month or less than 10 half-lives, whichever is shorter, of the respective drug prior to administration or during the trial
- Use of acetylsalicylic acid (ASA)-containing over-the-counter medications, clopidogrel or ticlopidine or dipyridamole, chronic administration of non-steroidal anti-inflammatory drugs (NSAIDs) (cyclooxygenase-2 (COX-2) inhibitors excluded), coumadin like anticoagulants, chronic use of corticosteroids, heparin and fibrinolytic agents within 14 days prior to administration or during the trial.
- Participation in another trial with an investigational drug within three months prior to administration or during the trial
- Smoker (> 10 cigarettes/day or > 3 cigars/day or > 3 pipes/day)
- Inability to refrain from smoking on trial days
- Alcohol abuse (more than 21unit/week; one unit was approximately half a pint of beer, a small glass of wine or one measure of spirits)
- History of drug abuse
- Blood donation (more than 100 mL within three months prior to screening administration and any blood donation from screening to end-of-study examination)
- Excessive physical activities (within one week prior to administration or during the trial and until end-of-study examination)
- Any laboratory value outside the reference range that was of clinical relevance
- Inability to comply with dietary regimen of study centre
- Known hypersensitivity to the drug or its excipients
- History of any familial bleeding disorder
- Thrombocytes < 150000/μL
Tanulási terv
Ez a rész a vizsgálati terv részleteit tartalmazza, beleértve a vizsgálat megtervezését és a vizsgálat mérését.
Hogyan készül a tanulmány?
Tervezési részletek
- Elsődleges cél: Kezelés
- Kiosztás: Nem véletlenszerű
- Beavatkozó modell: Párhuzamos hozzárendelés
- Maszkolás: Nincs (Open Label)
Fegyverek és beavatkozások
Résztvevő csoport / kar |
Beavatkozás / kezelés |
---|---|
Kísérleti: BIBR 1048 MS low dose
|
|
Kísérleti: BIBR 1048 MS medium dose
|
|
Kísérleti: BIBR 1048 MS high dose
|
Mit mér a tanulmány?
Elsődleges eredményintézkedések
Eredménymérő |
Időkeret |
---|---|
Change in vital signs
Időkeret: Baseline and up to day 26
|
Baseline and up to day 26
|
Change in 12-lead electrocardiogram (ECG)
Időkeret: Baseline and up to day 26
|
Baseline and up to day 26
|
Change in clinical laboratory tests
Időkeret: Baseline and up to day 26
|
Baseline and up to day 26
|
Occurence of adverse events
Időkeret: Up to day 26
|
Up to day 26
|
Másodlagos eredményintézkedések
Eredménymérő |
Időkeret |
---|---|
Area under the curve (AUC) from 0-24 hours for activated partial thromboplastin time (aPTT)
Időkeret: Day 1 and 12
|
Day 1 and 12
|
AUC from 0-24 hours for ecarin clotting time (ECT)
Időkeret: Day 1 and 12
|
Day 1 and 12
|
Change in thrombin time (TT)
Időkeret: Baseline and up to 72 hours after administration on day 1 and 12
|
Baseline and up to 72 hours after administration on day 1 and 12
|
Change in prothrombin time (PT) expressed as international normalised ratio (INR)
Időkeret: Baseline and up to 72 hours after administration on day 1 and 12
|
Baseline and up to 72 hours after administration on day 1 and 12
|
Maximum value of aPTT
Időkeret: Up to 72 hours after administration on day 1 and 12
|
Up to 72 hours after administration on day 1 and 12
|
Maximum value of ECT
Időkeret: Up to 72 hours after administration on day 1 and 12
|
Up to 72 hours after administration on day 1 and 12
|
Change in ECT
Időkeret: Baseline and up to 72 hours after administration on day 1 and 12
|
Baseline and up to 72 hours after administration on day 1 and 12
|
Change in aPTT
Időkeret: Baseline and up to 72 hours after administration on day 1 and 12
|
Baseline and up to 72 hours after administration on day 1 and 12
|
Cmax (maximum measured concentration of the analyte in plasma)
Időkeret: Up to 72 hours after administration on day 1
|
Up to 72 hours after administration on day 1
|
tmax (time from dosing to maximum measured concentration of the analyte in plasma)
Időkeret: Up to 72 hours after administration on day 1
|
Up to 72 hours after administration on day 1
|
AUCτ,1 (area under the concentration-time curve of the analyte in plasma over a uniform dosing interval τ after administration of the single dose on day 1)
Időkeret: Up to 72 hours after administration on day 1
|
Up to 72 hours after administration on day 1
|
AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable drug plasma concentration)
Időkeret: Up to 72 hours after administration on day 1
|
Up to 72 hours after administration on day 1
|
AUC0-∞ (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)
Időkeret: Up to 72 hours after administration on day 1
|
Up to 72 hours after administration on day 1
|
λz (terminal rate constant in plasma)
Időkeret: Up to 72 hours after administration on day 1
|
Up to 72 hours after administration on day 1
|
t1/2 (terminal half-life of the analyte in plasma)
Időkeret: Up to 72 hours after administration on day 1
|
Up to 72 hours after administration on day 1
|
MRTpo (mean residence time of the analyte in the body after po administration)
Időkeret: Up to 72 hours after administration on day 1
|
Up to 72 hours after administration on day 1
|
CL/F (apparent clearance of the analyte in plasma following extravascular administration)
Időkeret: Up to 72 hours after administration on day 1
|
Up to 72 hours after administration on day 1
|
Vz/F (apparent volume of distribution during the terminal phase λz following an extravascular administration)
Időkeret: Up to 72 hours after administration on day 1
|
Up to 72 hours after administration on day 1
|
Aet1-t2 (amount of analyte that is eliminated in urine from the time point t1 to time point t2)
Időkeret: Up to 72 hours after administration on day 1
|
Up to 72 hours after administration on day 1
|
fet1-t2 (fraction of analyte eliminated in urine from time point t1 to time point t2)
Időkeret: Up to 72 hours after administration on day 1
|
Up to 72 hours after administration on day 1
|
CLR,t1-t2 (renal clearance of the analyte from the time point t1 until the time point t2)
Időkeret: Up to 72 hours after administration on day 1
|
Up to 72 hours after administration on day 1
|
Cmax,ss (maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ)
Időkeret: Up to 72 hours after the last dose on day 12
|
Up to 72 hours after the last dose on day 12
|
tmax,ss (time from last dosing to maximum concentration of the analyte in plasma at steady state)
Időkeret: Up to 72 hours after the last dose on day 12
|
Up to 72 hours after the last dose on day 12
|
Cmin,ss (minimum concentration of the analyte in plasma at steady state over a uniform dosing interval τ)
Időkeret: Up to 72 hours after the last dose on day 12
|
Up to 72 hours after the last dose on day 12
|
AUCτ,ss (area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval τ)
Időkeret: Up to 72 hours after the last dose on day 12
|
Up to 72 hours after the last dose on day 12
|
λz,ss (terminal rate constant in plasma at steady state)
Időkeret: Up to 72 hours after the last dose on day 12
|
Up to 72 hours after the last dose on day 12
|
t1/2,ss (terminal half-life of the analyte in plasma at steady state)
Időkeret: Up to 72 hours after the last dose on day 12
|
Up to 72 hours after the last dose on day 12
|
MRTpo,ss (mean residence time of the analyte in the body at steady state after po administration)
Időkeret: Up to 72 hours after the last dose on day 12
|
Up to 72 hours after the last dose on day 12
|
CL/F,ss (apparent clearance of the analyte in the plasma at steady state after extravascular multiple dose administration)
Időkeret: Up to 72 hours after the last dose on day 12
|
Up to 72 hours after the last dose on day 12
|
Vz/F,ss (apparent volume of distribution during the terminal phase λz at steady state following extravascular administration)
Időkeret: Up to 72 hours after the last dose on day 12
|
Up to 72 hours after the last dose on day 12
|
Aet1-t2,ss (amount of analyte that is eliminated in urine at steady state from the time point t1 to time point t2)
Időkeret: Up to 72 hours after the last dose on day 12
|
Up to 72 hours after the last dose on day 12
|
fet1-t2,ss (fraction of analyte eliminated in urine at steady state from time point t1 to time point t2)
Időkeret: Up to 72 hours after the last dose on day 12
|
Up to 72 hours after the last dose on day 12
|
CLR,t1-t2,ss (renal clearance of the analyte in plasma from the time point t1 until the time point t2 at steady state)
Időkeret: Up to 72 hours after the last dose on day 12
|
Up to 72 hours after the last dose on day 12
|
Accumulation ratio RA,Cmax,7 based on Cmax
Időkeret: Day 6 to day 15
|
Day 6 to day 15
|
Accumulation ratio RA,AUC,7 based on AUCτ (only for 150 mg and 220 mg q.d. groups)
Időkeret: Day 6 to day 15
|
Day 6 to day 15
|
Linearity index (LI) based on AUC (only for 150 mg and 220 mg q.d. groups)
Időkeret: Day 6 to day 15
|
Day 6 to day 15
|
Együttműködők és nyomozók
Itt találhatja meg a tanulmányban érintett személyeket és szervezeteket.
Szponzor
Publikációk és hasznos linkek
A vizsgálattal kapcsolatos információk beviteléért felelős személy önkéntesen bocsátja rendelkezésre ezeket a kiadványokat. Ezek bármiről szólhatnak, ami a tanulmányhoz kapcsolódik.
Hasznos linkek
Tanulmányi rekorddátumok
Ezek a dátumok nyomon követik a ClinicalTrials.gov webhelyre benyújtott vizsgálati rekordok és összefoglaló eredmények benyújtásának folyamatát. A vizsgálati feljegyzéseket és a jelentett eredményeket a Nemzeti Orvostudományi Könyvtár (NLM) felülvizsgálja, hogy megbizonyosodjon arról, hogy megfelelnek-e az adott minőség-ellenőrzési szabványoknak, mielőtt közzéteszik őket a nyilvános weboldalon.
Tanulmány főbb dátumok
Tanulmány kezdete
2004. december 1.
Elsődleges befejezés (Tényleges)
2005. június 1.
Tanulmányi regisztráció dátumai
Először benyújtva
2014. június 20.
Először nyújtották be, amely megfelel a minőségbiztosítási kritériumoknak
2014. június 20.
Első közzététel (Becslés)
2014. június 23.
Tanulmányi rekordok frissítései
Utolsó frissítés közzétéve (Tényleges)
2018. augusztus 31.
Az utolsó frissítés elküldve, amely megfelel a minőségbiztosítási kritériumoknak
2018. augusztus 29.
Utolsó ellenőrzés
2018. augusztus 1.
Több információ
A tanulmányhoz kapcsolódó kifejezések
További vonatkozó MeSH feltételek
Egyéb vizsgálati azonosító számok
- 1160.29
Ezt az információt közvetlenül a clinicaltrials.gov webhelyről szereztük be, változtatás nélkül. Ha bármilyen kérése van vizsgálati adatainak módosítására, eltávolítására vagy frissítésére, kérjük, írjon a következő címre: register@clinicaltrials.gov. Amint a változás bevezetésre kerül a clinicaltrials.gov oldalon, ez a webhelyünkön is automatikusan frissül. .
Klinikai vizsgálatok a Egészséges
-
ArdelyxBefejezveHealthy Volunteers Food Interaction StudyEgyesült Államok
-
AstraZenecaBefejezveHealthy Volunteers Bioekvivalencia vagy Biohasznosulási tanulmányEgyesült Királyság
Klinikai vizsgálatok a BIBR 1048 MS low dose
-
Boehringer IngelheimBefejezve
-
Boehringer IngelheimBefejezve
-
Boehringer IngelheimBefejezve
-
Boehringer IngelheimBefejezve
-
Boehringer IngelheimBefejezve
-
Boehringer IngelheimBefejezve
-
Boehringer IngelheimBefejezve
-
Boehringer IngelheimBefejezve
-
Boehringer IngelheimBefejezve
-
Boehringer IngelheimBefejezve